Premium
Pharmacokinetics of Intravenous and Oral Levofloxacin in Critically Ill Adults in a Medical Intensive Care Unit
Author(s) -
Rebuck Jill A.,
Fish Douglas N.,
Abraham Edward
Publication year - 2002
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.22.15.1216.33484
Subject(s) - cmin , levofloxacin , pharmacokinetics , medicine , cmax , volume of distribution , intensive care unit , dosing , critically ill , oral administration , anesthesia , pharmacodynamics , pharmacology , antibiotics , chemistry , biochemistry
Study Objective. To characterize the pharmacokinetic disposition of intravenous and oral levofloxacin in critically ill adults. Design. Prospective, open‐label study. Setting. University teaching hospital. Patients. Thirty critically ill patients in a medical intensive care unit (ICU). Interventions. All patients received levofloxacin as part of their routine medical care. Pharmacokinetic evaluations were performed in 28 patients receiving intravenous levofloxacin. Ten of these patients subsequently were switched to oral levofloxacin and underwent a second pharmacokinetic evaluation during oral therapy. Measurements and Main Results. Mean ± SD levofloxacin half‐life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 ± 1.7 hours, 134 ± 35 ml/minute, and 1.2 ± 0.3 L/kg, respectively. Maximum and minimum serum concentrations (C max and C min ) and area under the serum concentration‐time curve from 0–24 hours (AUC0‐24) in patients receiving levofloxacin 500 mg intravenously were 7.5 ± 0.8 mg/L, 1.0 ± 0.5 mg/L, and 66.1 ± 15.7 mg · hour/L, respectively. Observed C max , C min , and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 ± 1.1 mg/L, 0.8 ± 0.4 mg/L, and 1.3 ± 0.4 hours, respectively These values were significantly different (p<0.05) from those observed after intravenous dosing in the same patients; other pharmacokinetic parameters were similar. Statistically significant increases (p<0.05) in C max , C min , half‐life, and AUC 0–24 were found in critically ill patients administered multiple doses of intravenous levofloxacin compared with historical data from healthy volunteers. Conclusions. The dosage regimen of intravenous levofloxacin 500 mg once/day appears adequate for most pathogens found in critically ill patients with normal renal function. Less susceptible pathogens may require an increased daily dose for more optimal therapy. Orally administered levofloxacin appears to be well absorbed in selected ICU patients and has pharmacokinetics similar to those of intravenously administered levofloxacin.